Stayble Therapeutics Investor Relations Material
Latest events
CEO Sitdown with Kalqyl Q4 2023
Stayble Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Stayble Therapeutics
Access all reports
Stayble Therapeutics AB develops injectable treatment for chronic low back pain triggered by disc degeneration. Its portfolio includes StaYble, a combination of two drugs that are already approved for use in humans and administered as separate mechanisms at complementary sites of action, with the goal of achieving synergy, which is the treatment of pain through several independent but related mechanisms.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
STABL
Country
🇸🇪 Sweden